Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring

doi:10.3748/wjg.v27.i37.6231

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 27, Issue 37

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7247)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-4) series.

Item

Count

PDF

493

WORD

154

HTML

4582

Figures (1-1)

387

Tables (1-4)

585

Sum=6201

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

388

Download

658

Sum=1046

Oct 7, 2021 (publication date) through Dec 23, 2024

Times Cited of This Article

Times Cited (15)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastroenterol. Oct 7, 2021; 27(37): 6231-6247
Published online Oct 7, 2021. doi: 10.3748/wjg.v27.i37.6231

Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring

Farah Albader, Petra Anna Golovics, Lorant Gonczi, Talat Bessissow, Waqqas Afif, Peter Laszlo Lakatos

Farah Albader, Department of Internal Medicine, McGill University, Montreal H3G1A4, Quebec, Canada

Petra Anna Golovics, Division of Gastroenterology, Hungarian Defence Forces, Medical Centre, Budapest H-1062, Hungary

Petra Anna Golovics, Waqqas Afif, Peter Laszlo Lakatos, Division of Gastroenterology, McGill University, Montreal H3G 1A4, Quebec, Canada

Lorant Gonczi, First Department of Medicine, Semmelweis University, Budapest H-1083, Hungary

Talat Bessissow, Division of Gastroenterology, McGill University Health Centre, Montreal H3G 1A4, Quebec, Canada

Author contributions: All authors contributed equally to this paper with regards to the conception and structure of the paper in addition to the literature review, drafting and revision with unanimous approval of the final version.

Conflict-of-interest statement: Authors declare no conflict of interest.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Peter Laszlo Lakatos, MD, PhD, Professor, Staff Physician, Division of Gastroenterology, McGill University, 1650 Cedar Avenue, Montreal H3G 1A4, Quebec, Canada. kislakpet99@gmail.com

Received: March 19, 2021
Peer-review started: March 19, 2021
First decision: May 1, 2021
Revised: May 8, 2021
Accepted: August 31, 2021
Article in press: August 31, 2021
Published online: October 7, 2021
Processing time: 193 Days and 14.5 Hours

Core Tip

Core Tip: In this review, we discuss the existing studies that looked at both proactive and reactive therapeutic drug monitoring (TDM) and concluded that in current practice, reactive TDM has been shown to be useful. When used as an adjunct to clinical assessment and biomarkers in patients with treatment failure, TDM has proven to be a valuable tool for subsequent management.